JPWO2021224499A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021224499A5 JPWO2021224499A5 JP2022567357A JP2022567357A JPWO2021224499A5 JP WO2021224499 A5 JPWO2021224499 A5 JP WO2021224499A5 JP 2022567357 A JP2022567357 A JP 2022567357A JP 2022567357 A JP2022567357 A JP 2022567357A JP WO2021224499 A5 JPWO2021224499 A5 JP WO2021224499A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- dose
- composition according
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 67
- 230000037452 priming Effects 0.000 claims 10
- 238000011282 treatment Methods 0.000 claims 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 238000009101 premedication Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 230000003442 weekly effect Effects 0.000 claims 7
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 206010052015 cytokine release syndrome Diseases 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 201000003444 follicular lymphoma Diseases 0.000 claims 4
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 4
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 claims 3
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 3
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 239000002221 antipyretic Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 229960000106 biosimilars Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 229960000520 diphenhydramine Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 208000010380 tumor lysis syndrome Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022212P | 2020-05-08 | 2020-05-08 | |
| US63/022,212 | 2020-05-08 | ||
| US202063078667P | 2020-09-15 | 2020-09-15 | |
| US63/078,667 | 2020-09-15 | ||
| US202063121690P | 2020-12-04 | 2020-12-04 | |
| US63/121,690 | 2020-12-04 | ||
| PCT/EP2021/062231 WO2021224499A1 (en) | 2020-05-08 | 2021-05-07 | Bispecific antibodies against cd3 and cd20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524149A JP2023524149A (ja) | 2023-06-08 |
| JPWO2021224499A5 true JPWO2021224499A5 (he) | 2024-05-17 |
Family
ID=75870647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567357A Pending JP2023524149A (ja) | 2020-05-08 | 2021-05-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230227570A1 (he) |
| EP (1) | EP4146175A1 (he) |
| JP (1) | JP2023524149A (he) |
| KR (1) | KR20230008775A (he) |
| CN (1) | CN115916166A (he) |
| AU (1) | AU2021267402A1 (he) |
| BR (1) | BR112022022730A2 (he) |
| CA (1) | CA3176436A1 (he) |
| IL (1) | IL297986A (he) |
| MX (1) | MX2022013797A (he) |
| WO (1) | WO2021224499A1 (he) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| CA3192255A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| CA3192251A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| EP4210742A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| KR20230066391A (ko) * | 2020-09-10 | 2023-05-15 | 젠맵 에이/에스 | 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 |
| WO2023198839A2 (en) | 2022-04-13 | 2023-10-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| WO2023204290A1 (ja) * | 2022-04-21 | 2023-10-26 | 愛知県 | 多重特異性ナノ粒子 |
| WO2024094822A1 (en) | 2022-11-02 | 2024-05-10 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating richter's syndrome |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| EP2330130B1 (en) | 2002-10-17 | 2014-08-27 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| SG10201600950TA (en) | 2005-11-28 | 2016-03-30 | Genmab As | Recombinant monovalent antibodies and methods for production thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| SG10201800757TA (en) | 2010-04-20 | 2018-02-27 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| SG10201805291TA (en) | 2011-10-27 | 2018-08-30 | Genmab As | Production of heterodimeric proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| CN113248615A (zh) * | 2013-07-05 | 2021-08-13 | 根马布股份公司 | 人源化或嵌合cd3抗体 |
| CN107660214B (zh) | 2015-01-08 | 2022-02-08 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| CN108368172B (zh) * | 2015-07-15 | 2022-06-14 | 根马布股份公司 | 人源化或嵌合cd3抗体 |
| WO2017210485A1 (en) * | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma |
| KR20200119275A (ko) * | 2018-02-09 | 2020-10-19 | 젠맵 에이/에스 | Cd3 및 cd20에 대해 지정된 이중특이적 항체를 포함하는 제약 조성물 및 그의 용도 |
| CA3149333A1 (en) * | 2019-08-15 | 2021-02-18 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
| EP4210742A1 (en) * | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| CA3192255A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| KR20230066391A (ko) * | 2020-09-10 | 2023-05-15 | 젠맵 에이/에스 | 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 |
-
2021
- 2021-05-07 CN CN202180041298.9A patent/CN115916166A/zh active Pending
- 2021-05-07 IL IL297986A patent/IL297986A/he unknown
- 2021-05-07 JP JP2022567357A patent/JP2023524149A/ja active Pending
- 2021-05-07 KR KR1020227042426A patent/KR20230008775A/ko active Search and Examination
- 2021-05-07 US US17/923,317 patent/US20230227570A1/en active Pending
- 2021-05-07 WO PCT/EP2021/062231 patent/WO2021224499A1/en unknown
- 2021-05-07 BR BR112022022730A patent/BR112022022730A2/pt unknown
- 2021-05-07 MX MX2022013797A patent/MX2022013797A/es unknown
- 2021-05-07 US US17/314,946 patent/US20210371538A1/en active Pending
- 2021-05-07 EP EP21724290.8A patent/EP4146175A1/en active Pending
- 2021-05-07 AU AU2021267402A patent/AU2021267402A1/en active Pending
- 2021-05-07 CA CA3176436A patent/CA3176436A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503260A5 (he) | ||
| KR20200020902A (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| JPWO2021183359A5 (he) | ||
| JP2020516240A5 (he) | ||
| JP2021501162A5 (he) | ||
| JP2020515577A5 (he) | ||
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| JP6278536B2 (ja) | 関節炎治療 | |
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| JPWO2021224499A5 (he) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2019532970A5 (he) | ||
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JPWO2019228514A5 (he) | ||
| CN112996540A (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| JPWO2019152743A5 (he) | ||
| JPWO2020206033A5 (he) | ||
| IL311796A (he) | נוגדנים אנטי-גלקטין-9 ושימושים טיפוליים שלהם | |
| JPWO2021113701A5 (he) | ||
| RU2023130537A (ru) | Введение доз для лечения биспецифическим антителом к cd20/cd3 | |
| JPWO2021195362A5 (he) | ||
| JPWO2020250033A5 (he) | ||
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи |